Neuropeptide Y and neurovascular control in skeletal muscle and skin

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 297, Issue 3, 2009, Pages

  Hodges, Gary J ^a   Jackson, Dwayne N ^a   Mattar, Louis ^a   Johnson, John M ^b   Shoemaker, J Kevin ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

BIBP3226; Blood flow control; Skeletal muscle blood flow; Skin blood flow

Indexed keywords

NEUROPEPTIDE Y; NEUROPEPTIDE Y1 RECEPTOR;

ADRENERGIC TRANSMISSION; AGING; COOLING; ENERGY METABOLISM; HEATING; HUMAN; MUSCLE BLOOD FLOW; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; SEX DIFFERENCE; SKELETAL MUSCLE; SKIN; SKIN BLOOD FLOW; SPRAGUE DAWLEY RAT; STRESS; VASOCONSTRICTION; VASODILATATION; VASOMOTOR REFLEX;

AGE FACTORS; ANIMALS; BLOOD PRESSURE; BLOOD VESSELS; FEMALE; HUMANS; MALE; MUSCLE, SKELETAL; NEUROPEPTIDE Y; NITRIC OXIDE; NOREPINEPHRINE; RATS; RECEPTORS, NEUROPEPTIDE Y; REFLEX; REGIONAL BLOOD FLOW; SEX FACTORS; SKIN; SKIN TEMPERATURE; VASOCONSTRICTION; VASODILATION; VASOMOTOR SYSTEM;

EID: 69249112284     PISSN: 03636119     EISSN: 15221490     Source Type: Journal    
DOI: 10.1152/ajpregu.00157.2009     Document Type: Review

References (115)

1. Andersen P, Saltin B. Maximal perfusion of skeletal muscle in man. J Physiol 366: 233-249, 1985.
2. Angus JA, Cocks TM, Satoh K. The alpha adrenoceptors on endothelial cells. Fed Proc 45: 2355-2359, 1986.
3. Armstrong RB, Delp MD, Goljan EF, Laughlin MH. Progressive elevations in muscle blood flow during prolonged exercise in swine J Appl Physiol 63: 1095-1099, 1987.
4. Bartfai T, Iverfeldt K, Fisone G, Serfozo P. Regulation of the release of coexisting neurotransmitters. Annu Rev Pharmacol Toxicol 28: 285-310, 1988.
5. Bennett LAT, Johnson JM, Stephens DP, Saad AR, Kellogg DL Jr. Evidence for a role for vasoactive intestinal peptide in active vasodilatation in the cutaneous vasculature in humans. J Physiol 552: 223-232, 2003.
6. Bergdahl A, Nilsson T, Cantera L, Nilsson L, Sun XY, Hedner T, Erlinge D, Valdemarson S, Edvinsson L. Neuropeptide Y potentiates noradrenaline-induced contraction through the neuropeptide Y Y1 receptor. Eur J Pharmacol 316: 59-64, 1996.
7. Berglund MM, Holmberg SK, Eriksson H, Gedda K, Maffrand JP, Serradeil-Le Gal C, Chhajlani V, Grundemar L, Larhammar D. The cloned guinea pig neuropeptide Y receptor Y1 conforms to other mammalian Y1 receptors. Peptides 20: 1043-1053, 1999.
8. Bini G, Hagbarth KE, Hynninen P, Wallin BG. Regional similarities and differences in thermoregulatory vaso- and sudomotor tone. J Physiol 306: 553-565, 1980.
9. Bischoff A, Gerbracht A, Michel MC. Gender and hypertension interact to regulate neuropeptide Y receptor responsiveness. Naunyn Schmiedebergs Arch Pharmacol 361: 173-180, 2000.
10. Bouder TG, Huffman LJ, Hedge GA. Effects of vasoactive intestinal peptide on vascular conductance are unaffected by anesthesia. Am J Physiol Regul Integr Comp Physiol 255: R968-R973, 1988.
11. Bradley E, Law A, Bell D, Johnson CD. Effects of varying impulse number on cotransmitter contributions to sympathetic vasoconstriction in rat tail artery. Am J Physiol Heart Circ Physiol 284: H2007-H2014, 2003.
12. Brengelmann GL, Savage MV. Temperature regulation in the neutral zone. Ann NY Acad Sci 813: 39-50, 1997.
13. Buckwalter JB, Hamann JJ, Clifford PS. Neuropeptide Y1 receptor vasoconstriction in exercising canine skeletal muscles. J Appl Physiol 99(6):2115-2120, 2005.
14. 2 receptors. Br J Pharmacol 140: 422-430, 2003.
15. Cocks TM, Angus JA. Endothelium-dependent relaxation of coronary arteries by noradrenaline and serotonin. Nature 305: 627-630, 1983.
16. 2- adrenoceptors and Y1 neuropeptide Y receptors to the blunting of sympathetic vasoconstriction induced by systemic hypoxia in the rat. J Physiol 582: 1349-1359, 2007.
17. Dahlof C, Dahlof P, Lundberg JM. Neuropeptide Y (NPY): enhancement of blood pressure increase upon alpha-adrenoceptor activation and direct pressor effects in pithed rats. Eur J Pharmacol 109: 289-292, 1985.
18. Delp MD, O'Leary DD. Integrative control of the skeletal muscle microcirculation in the maintenance of arterial pressure during exercise J Appl Physiol 97: 1112-1118, 2004.
19. De Camilli P, Jahn R. Pathways to regulated exocytosis in neurons. Annu Rev Physiol 52, 625-645, 1990.
20. De Potter WP, Kurzawa R, Miserez B, Coen EP. Evidence against differential release of noradrenaline, neuropeptide Y, and dopamine-beta- hydroxylase from adrenergic nerves in the isolated perfused sheep spleen. Synapse 19: 67-76, 1995.
21. De Potter WP, Partoens P, Schoups A, Llona I, Coen EP. Noradrenergic neurons release both noradrenaline and neuropeptide Y from a single pool: the large dense cored vesicles. Synapse 25: 44-55, 1997.
22. De Potter WP, Partoens P, Strecker S. Noradrenaline storing vesicles in sympathetic neurons and their role in neurotransmitter release: an historical overview of controversial issues. Neurochem Res 22: 911-919, 1997.
23. Dinenno FA, Jones PP, Seals DR, Tanaka H. Age-associated arterial wall thickening is related to elevations in sympathetic activity in healthy humans. Am J Physiol Heart Circ Physiol 278: H1205-H1210, 2000.
24. Doods HN, Wienen W, Entzeroth M, Rudolf K, Eberlein W, Engel W, Wieland HA. Pharmacological characterization of the selective nonpeptide neuropeptide Y Y1 receptor antagonist BIBP 3226. J Pharmacol Exp Ther 275: 136-142, 1995.
25. Doods H, Gaida W, Wieland HA, Dollinger H, Schnorrenberg G, Esser F, Engel W, Eberlein W, Rudolf K. BIIE0246: a selective and high affinity neuropeptide Y Y(2) receptor antagonist. Eur J Pharmacol 384: R3-R5, 1999.
26. Dumont Y, Fournier A, St-Pierre S, Quirion R. Comparative characterization and autoradiographic distribution of neuropeptide Y receptor subtypes in the rat brain. J Neurosci 13: 73-86, 1993.
27. Edvinsson L, Ekblad E, Hakanson R, Wahlestedt C. Neuropeptide Y potentiates the effect of various vasoconstrictor agents on rabbit blood vessels. Br J Pharmacol 83: 519-525, 1984.
28. Ekblad E, Edvinsson L, Wahlestedt C, Uddman R, Hakanson R, Sundler F. Neuropeptide Y co-exists and co-operates with noradrenaline in perivascular nerve fibers. Regul Pept 8: 225-235, 1984.
29. Ekelund U, Erlinge D. In vivo receptor characterization of neuropeptide Y-induced effects in consecutive vascular sections of cat skeletal muscle. Br J Pharmacol 120: 387-392, 1997.
30. Erami C, Zhang H, Ho JG, French DM, Faber JE. Alpha(1)- adrenoceptor stimulation directly induces growth of vascular wall in vivo. Am J Physiol Heart Circ Physiol 283: H1577-H1587, 2002.
31. Eva C, Keinanen K, Monyer H, Seeburg P, Sprengel R. Molecular cloning of a novel G protein-coupled receptor that may belong to the neuropeptide receptor family. FEBS Lett 271: 81-84, 1990.
32. Fallgren B, Arlock P, Edvinsson L. Neuropeptide Y potentiates noradrenaline-evoked vasoconstriction by an intracellular calcium-dependent mechanism. J Auton Nerv Syst 44: 151-159, 1993.
33. Franco-Cereceda A., Liska J. Neuropeptide Y Y1 receptors in vascular pharmacology. Eur J Pharmacol 349: 1-14, 1998.
34. Gerald C, Walker MW, Vaysse PJ, He C, Branchek TA, Weinshank RL. Expression cloning and pharmacological characterization of a human hippocampal neuropeptide Y/peptide YY Y2 receptor subtype. J Biol Chem 270: 26758-26761, 1995.
35. Glenn TC, Krause DN, Duckles SP. Vascular responses to neuropeptide Y are greater in female than male rats. Naunyn Schmiedebergs Arch Pharmacol 355: 111-118, 1997.
36. Glover WE. Increased sensitivity of rabbit ear artery to noradrenaline following perivascular nerve stimulation may be a response to neuropeptide Y released as cotransmitter. Clin Exp Pharmacol Physiol 12: 227-230, 1985.
37. Gradin KA, Buus CL, Li JY, Frobert O, Simonsen U. Neuropeptide Y2 receptors are involved in enhanced neurogenic vasoconstriction in spontaneously hypertensive rats. Brit J Pharmacol 148: 703-713, 2006.
38. Grassi G, Quarti-Trevano F, Seravalle G, Dell'Oro R. Cardiovascular risk and adrenergic overdrive in the metabolic syndrome. Nutr Metab Cardiovasc Dis 17: 473-481, 2007.
39. Grundemar L. Multiple receptors and multiple actions. In: Neuropeptide Y and Drug Development, edited by Grundemar L. and Bloom SR. San Diego, CA: Academic, 1997.
40. Heath ME. Neuropeptide Y and Y1 receptor agonists increase blood flow through arteriovenous anastomoses in rat tail. J Appl Physiol 85: 301-309, 1998.
41. Herzog H, Hort YJ, Ball HJ, Hayes G, Shine J, Selbie LA. Cloned human neuropeptide Y receptor couples to two different second messenger systems. Proc Natl Acad Sci USA 89: 5794-5798, 1992.
42. Higuchi H, Yang HY, Sabol SL. Rat neuropeptide Y precursor gene expression mRNA structure, tissue distribution, and regulation by glucocorticoids, cyclic AMP, and phorbol ester. J Biol Chem 263: 6288-6295, 1988.
43. Hodges GJ, Kosiba WA, Zhao K, Johnson JM. The involvement of norepinephrine, neuropeptide Y, and nitric oxide in the cutaneous vasodilator response to local heating in humans. J Appl Physiol 105: 233-240, 2008.
44. Hodges GJ, Zhao K, Kosiba WA, Johnson JM. The involvement of nitric oxide in the cutaneous vasoconstrictor response to local cooling in humans. J Physiol 574: 849-857, 2006.
45. Itoi K, Mouri T, Takahashi K, Sasaki S, Imai Y, Yoshinaga K. Synergistic pressor action of neuropeptide Y and norepinephrine in conscious rats. J Hypertens Suppl 4: S247-S250, 1986.
46. Jackson DN, Noble EG, Shoemaker JK. Y1- and α1-receptor control of basal hindlimb vascular tone. Am J Physiol Regul Integr Comp Physiol 287: R228-R233, 2004.
47. Jackson DN, Milne KJ, Noble EG, Shoemaker JK. Gender-modulated endogenous baseline neuropeptide Y Y1-receptor activation in the hindlimb of Sprague-Dawley rats. J Physiol 562: 285-294, 2005.
48. Jackson DN, Milne KJ, Noble EG, Shoemaker JK. Neuropeptide Y bioavailability is suppressed in the hindlimb of female Sprague-Dawley rats. J Physiol 568: 573-581, 2005.
49. Johnson JM, Proppe DW. Cardiovascular adjustments to heat stress. In: Handbook of Physiology. Environmental Physiology. Bethesda, MD: Am. Physiol. Soc., 1996, sect. 4, vol. 1, chapt. 11, p. 215-243.
50. Johnson JM, Yen TC, Zhao K, Kosiba WA. Sympathetic, sensory, and nonneuronal contributions to the cutaneous vasoconstrictor response to local cooling. Am J Physiol Heart Circ Physiol 288: H1573-H1579, 2005.
51. Jones PP, Snitker S, Skinner JS, Ravussin E. Gender differences in muscle sympathetic nerve activity: effect of body fat distribution. Am J Physiol Endocrinol Metab 270: E363-E366, 1996.
52. Kasakov L, Ellis J, Kirkpatrick K, Milner P, Burnstock G. Direct evidence for concomitant release of noradrenaline, adenosine 5′-triphosphate and neuropeptide Y from sympathetic nerve supplying the guinea-pig vas deferens. J Auton Nerv Syst 22: 75-82, 1988.
53. Kaye DM, Lefkovits J, Jennings GL, Bergin P, Broughton A, Esler MD. Adverse consequences of high sympathetic nervous activity in the failing human heart. J Am Coll Cardiol 26: 1257-1263, 1995.
54. Kellogg DL Jr, Johnson JM, Kosiba WA. Selective abolition of adrenergic vasoconstrictor responses in skin by local iontophoresis of bretylium. Am J Physiol Heart Circ Physiol 257: H1599-H1606, 1989.
55. Kellogg DL Jr, Pérgola PE, . Piest KL, Kosiba WA, Crandall CG, Grossmann M, and. Johnson JM. Cutaneous active vasodilation in humans is mediated by cholinergic nerve cotransmission. Circ Res 77: 1222-1228, 1995.
56. Kelly RB. Storage and release of neurotransmitters. Cell 72 Suppl: 43-53, 1993.
57. Kuo LE, Abe K, Zukowska Z. Stress, NPY and vascular remodeling: Implications for stress-related diseases. Peptides 28: 435-440, 2007.
58. Larhammar D, Blomqvist AG, Yee F, Jazin E, Yoo H, Wahlested C. Cloning and functional expression of a human neuropeptide Y/peptide YY receptor of the Y1 type. J Bio Chem 267: 10935-10938, 1992.
59. Linder L, Lautenschlager BM, Haefeli WE. Subconstrictor doses of neuropeptide Y potentiate alpha 1-adrenergic venoconstriction in vivo. Hypertension 28: 483-487, 1996.
60. Lobaugh LA, Blackshear PJ. Neuropeptide Y stimulation of myosin light chain phosphorylation in cultured aortic smooth muscle cells. J Biol Chem 265: 18393-18399, 1990.
61. Lundberg JM. Pharmacology of cotransmission in the autonomic nervous system: integrative aspects on amines, neuropeptides, adenosine triphosphate, amino acids and nitric oxide. Pharmacol Rev 48: 113-178, 1996.
62. Lundberg JM, Franco-Cereceda A, Lou YP, Modin A, Pernow J. Differential release of classical transmitters and peptides. Adv Second Messenger Phosphoprotein Res 29: 223-234, 1994.
63. Lundberg JM, Martinsson A, Hemsén A, Theodorsson-Norheim E, Svedenhag J, Ekblom B, Hjemdahl P. Co-release of neuropeptide Y and catecholamines during physical exercise in man. Biochem Biophys Res Commun 133: 30-36, 1985.
64. Lundberg JM, Modin A. Inhibtion of sympathetic vasoconstriction in pigs in vivo by the neuropeptide Y-Y1 receptor antagonist BIBP 3226. Br J Pharm 116: 2971-2982, 1995.
65. Lundberg JM, Tatemoto K. Pancreatic polypeptide family (APP, BPP, NPY and PYY) in relation to sympathetic vasoconstriction resistant to alpha-adrenoceptor blockade. Acta Physiol Scand 116: 393-402, 1982.
66. Lundberg JM, Terenius L, Hökfelt T, Martling CR, Tatemoto K, Mutt V, Polak J, Bloom S, Goldstein M. Neuropeptide Y (NPY)-like immunoreactivity in peripheral noradrenergic neurons and effects of NPY on sympathetic function. Acta Physiol Scand 116: 477-480, 1982.
67. Malmstrom RE. Neuropeptide Y Y1 receptor mechanisms in sympathetic vascular control. Acta Physiol Scand Suppl 636: 1-55, 1997.
68. Malmstrom RE. Existence of both neuropeptide Y, Y1 and Y2 receptors in pig spleen: evidence using subtype-selective antagonists in vivo. Life Sci 69: 1999-2005, 2001.
69. Malmstrom RE, Lundberg JN, Weitzberg E. Effects of the neuropeptide Y Y2 receptor antagonist BIIE0246 on sympathetic transmitter release in the pig in vivo. Naunyn Schmiedebergs Arch Pharmacol 365: 106-111, 2002.
70. Malmstrom RE, Lundberg JO, Weitzberg E. Autoinhibitory function of the sympathetic prejunctional neuropeptide Y Y(2) receptor evidenced by BIIE0246. Eur J Pharmacol 439: 113-119, 2002.
71. Mancia G, Grassi G, Giannattasio C, Seravalle G. Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. Hypertension 34: 724-728, 1999.
72. Matsukawa K, Ninomiya I. Anesthetic effects on tonic and reflex renal sympathetic nerve activity in awake cats. Am J Physiol Regul Integr Comp Physiol 256: R371-R378, 1989.
73. Mentlein R, Dahms P, Grandt D, Krüger R. Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV. Regul Pept 49: 133-44, 1993.
74. Michel MC. Neuropeptide Y and Related Peptides. Handbook of Experimental Pharmacology, Heidelberg: Springer-Verlag, 2004, vol. 162.
75. Michel MC, Lewejohann K, Farke W, Bischoff A, Feth F, Rascher W. Regulation of NPY/NPY Y1 receptor/G protein system in rat brain cortex. Am J Physiol Regul Integr Comp Physiol 268: R192-R200, 1995.
76. Michel MC, Rascher W. Neuropeptide Y: a possible role in hypertension? J Hypertens 13: 385-395, 1995.
77. Minth CD, Bloom SR, Polak JM, Dixon JE. Cloning, characterization, and DNA sequence of a human cDNA encoding neuropeptide tyrosine. Proc Natl Acad Sci USA 81: 4577-4581, 1984.
78. Modin A, Pernow J, Lundberg JM. Evidence for two neuropeptide Y receptors mediating vasoconstriction. Eur J Pharmacol 203: 165-171, 1991.
79. Morris JL. Selective constriction of small cutaneous arteries by NPY matches distribution of NPY in sympathetic axons. Regul Pept 49: 225-236, 1994.
80. Morris JL. Cotransmission from sympathetic vasoconstrictor neurons to small cutaneous arteries in vivo. Am J Physiol Heart Circ Physiol 277: H58-H64, 1999.
81. Morris MJ, Russell AE, Kapoor V, Cain MD, Elliott JM, West MJ, Wing LM, Chalmers JP. Increases in plasma neuropeptide Y concentrations during sympathetic activation in man. J Auton Nerv Syst 2: 143-149, 1986.
82. Nilsson T, Erlinge D, Cantera L, Edvinsson L. Contractile effects of neuropeptide Y in human subcutaneous resistance arteries are mediated by Y1 receptors. 28: 764-768, 1996.
83. Ng AV, Callister R, Johnson DG, Seals DR. Age and gender influence muscle sympathetic nerve activity at rest in healthy humans. Hypertension 21: 498-503, 1993.
84. Pauletto P, Scannapieco G, Pessina AC. Sympathetic drive and vascular damage in hypertension and atherosclerosis. Hypertension 17 Suppl: III75-III81, 1991.
85. Pedrazzini T, Seydoux J, Kunstner P, Aubert JF, Grouzmann E, Beermann F, Brunner HR. Cardiovascular response, feeding behavior and locomotor activity in mice lacking the NPY Y1 receptor. Nat Med 4: 722-726, 1998.
86. Pons J, Kitlinska J, Ji H, Lee EW, and Zukowska Z. Mitogenic actions of neuropeptide Y in vascular smooth muscle cells: synergetic interactions with the beta-adrenergic system. Can J Physiol Pharmacol 81: 177-185, 2003.
87. Qureshi NU, Dayao EK, Shirali S, Zukowska-Grojec Z, Hauser GJ. Endogenous neuropeptide Y mediates vasoconstriction during endotoxic and hemorrhagic shock. Regul Pept 75-76: 215-220, 1998.
88. Revington M, McCloskey DI. Neuropeptide Y and control of vascular resistance in skeletal muscle. Regul Pept 23: 331-342, 1988.
89. Rudolf K, Eberlein W, Engel W, Wieland HA, Willim KD, Entzeroth M, Wienen W, Beck-Sickinger AG, Doods HN. The first highly potent and selective non-peptide neuropeptide Y Y1 receptor antagonist: BIBP3226. Eur J Pharmacol 271: R11-R13, 1994.
90. Shigeri Y, Fujimoto M. Neuropeptide Y stimulates DNA synthesis in vascular smooth muscle cells. Neurosci Lett 149: 19-22, 1993.
91. Shoemaker JK, Hogeman CS, Khan M, Kimmerly DS, Sinoway LI. Gender affects sympathetic and hemodynamic response to postural stress. Am J Physiol Heart Circ Physiol 281: H2028-H2035, 2001.
92. Smith-White MA, Hardy TA, Brock JA, Potter EK. Effects of a selective neuropeptide Y Y2 receptor antagonist, BIIE0246, on Y2 receptors at peripheral neuroeffector junctions. Br J Pharmacol 132: 861-868, 2001.
93. Statnick MA, Schober DA, Gackenheimer S, Johnson D, Beavers L, Mayne NG, Burnett JP, Gadski R, Gehlert DR. Characterization of the neuropeptide Y5 receptor in the human hypothalamus: a lack of correlation between Y5 mRNA levels and binding sites. Brain Res 810: 16-26, 1998.
94. Stephens DP, Aoki K, Kosiba WA, Johnson JM. Nonnoradrenergic mechanism of reflex cutaneous vasoconstriction in men. Am J Physiol Heart Circ Physiol 280: H1496-H1504, 2001.
95. Stephens DP, Bennett LA, Aoki K, Kosiba WA, Charkoudian N, Johnson JM. Sympathetic nonnoradrenergic cutaneous vasoconstriction in women is associated with reproductive hormone status. Am J Physiol Heart Circ Physiol 282: H264-H272, 2002.
96. Stephens DP, Saad AR, Bennett LA, Kosiba WA, Johnson JM. Neuropeptide Y antagonism reduces reflex cutaneous vasoconstriction in humans. Am J Physiol Heart Circ Physiol 287: H1404-H1409, 2004.
97. Sundler F, Böttcher G, Ekblad E, Håkanson R. PP, PYY, and NPY: Occurance and distribution in the periphery. In: The Biology of Neuropeptide Y and Related Peptides, edited by Colmers WF and Wahlestedt C. Humana Press, Tolowa, 1993.
98. Tatemoto K, Carlquist M, Mutt V. Neuropeptide Y - a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide. Nature 296: 659-660, 1982.
99. Teranishi Y, Tsuru H, Shimomura H, Amano T, Matsubayashi H. Compensatory vasoconstrictor effects of sodium pentobarbital on the hindquarters of conscious normotensive control and lumbar-sympathectomized Wistar rats. Auton Neurosci 82: 130-136, 2000.
100. Thompson CS, Kenney WL. Altered neurotransmitter control of reflex vasoconstriction in aged human skin. J Physiol 558: 697-704, 2004.
101. Tucker BJ, Peterson OW, Ziegler MG, Blantz RC. Analysis of adrenergic effects of the anesthetics Inactin and alpha-chloralose. Am J Physiol Renal Fluid Electrolyte Physiol 243: F253-F259, 1982.
102. Uddman R, Moller S, Nilsson T, Nystrom S, Ekstrand J, Edvinsson L. Neuropeptide Y Y1 and neuropeptide Y Y2 receptors in human cardiovascular tissues. Peptides 23: 927-934, 2002.
103. Vanhoutte PM, Miller VM. Alpha 2-adrenoceptors and endothelium-derived relaxing factor. Am J Med 87: 1S-5S, 1989.
104. Wahlestedt C, Edvinsson L, Ekblad E, Hakanson R. Neuropeptide Y potentiates noradrenaline-evoked vasoconstriction: mode of action. J Pharmacol Exp Ther 234: 735-741, 1985.
105. Wahlestedt C, Grundemar L, Hakanson R, Heilig M, Shen GH, Zukowska-Grojec Z, Reis DJ. Neuropeptide Y receptor subtypes, Y1 and Y2. Ann NY Acad Sci 611: 7-26, 1990.
106. Wocial B, Ignatowska-Switalska H, Pruszczyk P, Jedrusik P, Januszewicz A, Lapinski M, Januszewicz W, Zukowska-Grojec Z. Plasma neuropeptide Y and catecholamines in women and men with essential hypertension. Blood Press 4: 143-147, 1995.
107. Yamazaki F, Sone R, Zhao K, Alvarez GE, Kosiba WA, Johnson JM. Rate dependency and role of nitric oxide in the vascular response to direct cooling in human skin. J Appl Physiol 100: 42-50, 2006.
108. Zeng C, Zhou Y, Liu G, Sun W. The signal transduction pathway causing the synergistic hypertrophic effects of neuropeptide Y and norepinephrine on primary cardiomyocyte. Neuropeptides 35: 211-218, 2001.
109. Zhang H, Faber JE. Trophic effect of norepinephrine on arterial intima-media and adventitia is augmented by injury and mediated by different α1-adrenoceptor subtypes. Circ Res 89: 815-822, 2001.
110. Zhao XH, Sun XY, Edvinsson L, Hedner T. Does the neuropeptide Y Y1 receptor contribute to blood pressure control in the spontaneously hypertensive rat? J Hypertens 15: 19-27, 1997.
111. Zukowska-Grojec Z. Neuropeptide Y. A novel sympathetic stress hormone and more. Ann N Y Acad Sci 771: 219-233, 1995.
112. Zukowska-Grojec Z. Neuropeptide Y: an adrenergic cotransmitter, vasoconstrictor, and a nerve-derived vascular growth factor. Adv Pharmacol 42: 125-128, 1998.
113. Zukowska-Grojec Z, Shen GH, Capraro PA, Vaz CA. Cardiovascular, neuropeptide Y, and adrenergic responses in stress are sexually differentiated. Physiol Behav 49: 771-777, 1991.
114. Zukowska-Grojec Z, Vaz AC. Role of neuropeptide Y (NPY) in cardiovascular responses to stress. Synapse 2: 293-298, 1988.
115. Zukowska-Grojec Z, Wahlestedt C. Origin and actions of neuropeptide Y in the cardiovascular system. In: The Biology of Neuropeptide Y and Related Peptides, edited by Colmers W. F. and Wahlestedt C. Totowa, NJ: Humana Press, p. 315-388, 1993.